Novo Nordisk’s New Diabetes Combo Shows Potential To Best Lilly’s Mounjaro

Fierce Competition In Diabetes And Obesity Expected

 
• By Andrew McConaghie
Novo Nordisk
Novo Nordisk hopes to maintain its lead in diabetes and obesity treatment with its new combination

More from Clinical Trials

More from R&D